Luoxin Pharmaceutical signs licensing agreement with Austria-based Marinomed Biotech AG for Budesolv® Budesonide Nasal Spray
SHANGHAI, Oct. 21, 2021 /PRNewswire/ -- Shandong Luoxin Pharmaceutical Group Stock Co., Ltd. (''Shandong Luoxin''), a subsidiary of Luoxin Pharmaceutical Group Stock Co., Ltd. ("Luoxin Pharmaceutical" or "the company") , signed a licensing agreement with Austria-based Marinomed Biotech AG ("Marinomed"), whereby Shandong Luoxin will gain the exclusive rights for the development, manufacture, and commercialization of Budesolv® (Budesonide Nasal...
UNO Technologies announces collaboration with Aetos Pharma to further accelerate Malaysia’s healthcare tech transformation
SINGAPORE, Oct. 20, 2021 /PRNewswire/ -- UNO Technologies, a rapidly growing Medical Technology ("med tech") firm based in Singapore, has recently announced its expansion into the Malaysian market. As part of its regional strategy, UNO will team up with Aetos Pharma, a burgeoning Malaysian pharmaceutical upstart, to jointly propel the digital transformation of Malaysia's private healthcare sector. ...
IND Application for Phase III Clinical Study of Anti-HER2 Bispecific Antibody KN026 was Officially Accepted by CDE
SUZHOU, China, Oct. 21, 2021 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. (stock code: 1093.HK) jointly announced IND application for a phase III clinical study of recombinant humanized anti-HER2 bispecific antibody KN026 (KN026-306) was officially accepted by Center for Drug Evaluation (CDE), and will initiate a pivotal clinical study of KN026 combined with chemotherapy...
Red Ginseng’s possible COVID-19 Vaccine Adjuvant Effect gave out from Korean Ginseng Research Institute
SEOUL, South Korea, Oct. 21, 2021 /PRNewswire/ -- Korean Ginseng Research Institute, recently published research results on 'the vaccine adjuvant effect of red ginseng' and 'respiratory damage prevention effect'. It is said that red ginseng acts as a potential vaccine adjuvant by enhancing the efficacy of the vaccine. Red Ginseng The results of the study showed...
Korean Ginseng Research Institute Announces potential COVID-19 Vaccine Adjuvant Effect of Red Ginseng
SEOUL, South Korea, Oct. 21, 2021 /PRNewswire/ -- Korean Ginseng Research Institute, composing of over 130 outstanding researchers driving force behind innovation from KGC(Korea Ginseng Corp.), recently published a summary of research results on 'the vaccine adjuvant effect of red ginseng' and 'respiratory damage prevention effect'. It is said that red ginseng acts as a possible vaccine adjuvant...
Singapore-based Biosyngen receives 500 million yuan in investment
SINGAPORE, Oct. 21, 2021 /PRNewswire/ -- At the 12th Singapore-Guangdong Collaboration Council (SGCC) meeting held online on October 20, Singapore-based Biosyngen Pte. Ltd. ("Biosyngen") announced its partnership with wholly state-owned Chinese company Science City (Guangzhou) Investment Group Co., Ltd. ("SCI Group") whereby the two entities established the Biosyngen (China) biomedical base. ...
LifeWave donated to disaster areas due to heavy rainfall stroke in Japan
TOKYO, Oct. 21, 2021 /PRNewswire/ -- The record heavy rains that occurred from July to August of Reiwa 3 caused serious damage over a wide area from western Japan to eastern Japan. LifeWave donated to disaster areas due to heavy rainfall stroke in Japan According to a report by...
GenFleet Announces First Patient Dosed in Phase Ib/II Trial of TGF-β R1 Inhibitor in Combination with PD-1 Inhibitor in Global Multi-center Research
PERTH, Australia and TAIPEI and SHANGHAI, Oct. 21, 2021 /PRNewswire/ -- GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, today announced the first patient with metastatic sigmoid adenocarcinoma has been dosed in Perth, Australia in a phase Ib/II trial of GFH018 in combination with toripalimab (anti-PD-1 monoclonal antibody) as part of global multi-center...
Menarini Group and Radius Health Announce Positive Phase 3 Topline Results from the EMERALD Trial Evaluating Elacestrant in Breast Cancer
- Study met both primary endpoints in patients with ER+/HER2- advanced or mBC - Elacestrant becomes the first oral SERD with positive topline results in pivotal study as a monotherapy versus SoC for the treatment of ER+/HER2- advanced or mBC - Elacestrant extended PFS in the overall population and the...
EVERSANA and Intouch Group join forces, adding the premiere digital-first agency network to the market leader in next generation commercialization
CHICAGO and KANSAS CITY, Mo., Oct. 20, 2021 /PRNewswire/ -- EVERSANA™, the pioneer of next generation commercial services to the global life sciences industry, and Intouch Group®, a full-service global agency network serving the pharmaceutical industry, today announced that they signed an agreement to incorporate Intouch's industry-leading creative and media services,...
